Poster Abstracts • OFID 2017:4 (Suppl 1) • S129 inner colonies within the zone of inhibition around the fosfomycin disk confounds interpretation of susceptibility testing. The goal of this study was to estimate the frequency of these non-susceptible inner colony E. coli mutants and to identify their resistance mechanisms.
Background. Gastrointestinal (GI) Candida commensals may be a major source of invasive candidiasis and a hidden reservoir of antifungal resistance. Candida glabrata resistance rates have increased greater than those of other species. Here, we present a C. glabrata GI colonization model to explore how antifungal drugs affect resistance acquisition and systemic breakthrough infections.
Methods. Immunocompetent mice were treated with antibiotics to clear native GI bacteria and then inoculated via oral gavage with C. glabrata. Fecal samples were collected throughout the study to assess fungal GI colonization. Daily administration of caspofungin (CSF; 5 or 20 mg/kg i.p.), chitin synthase inhibitor nikkomycin Z (Nz; 100 mg/ kg oral), or saline was initiated on day 3 post inoculation. CSF-resistant colony frequencies were determined through selection of fecal samples on CSF-supplemented media, and FKS mutations were identified using the newly developed molecular beacon diagnostic assays. Dexamethasone was administered to induce immunosuppression. Upon completion of the experiment, blood, and organs were harvested and yeast burden levels determined.
Results. Daily therapeutic dosing (5 mg/kg) of CSF resulted in no reduction in fecal burdens, little resistance (0-10%), and organ breakthrough rates similar to control groups. Treatment with high dose (20 mg/kg) CSF caused a 2.5-log decrease in average burden, yet high levels (10/10 mice) of resistance (fks1/2 mutants) were observed following 5-9 days of treatment. Although breakthrough rates decreased in this group, yeast recovered from organs contained fks mutations. The largest reduction (3 log) in GI burdens was obtained within 3-5 days of high dose CSF plus Nz (100 mg/ kg; oral) treatment. However, echinocandin resistance was again observed from all mice (10/10) following 5-7 days of treatment. Treatment with the therapeutic dose plus Nz left GI burdens unchanged, but did significantly reduce organ breakthrough rates (20%; P < 0.05).
Conclusion. We have developed a C. glabrata GI colonization and dissemination model. Systemic breakthrough depends on both gut C. glabrata population composition and serum/tissue drug level. Background. DAP is used off-label for treatment of severe enterococcal infections. DAP resistance (R) in E. faecium has been associated with changes in LiaFSR, a three-component regulatory system that controls the cell envelope stress response to antibiotics. In particular, substitutions in LiaS (T120A) and LiaR (W73C) seem to predispose to development of DAP-R during therapy, without increasing the DAP MIC above the clinical breakpoint. Using a PK/PD model of simulated endocardial vegetations, we evaluated the genomic pathways for DAP-R under different DAP dose schemes.
Methods. A DAP-susceptible E. faecium (HOU503; MIC 3 mg/ml) harboring the above LiaSR substitutions, was subjected to simulated human doses of 6, 8, and 10 mg/kg/d in the model for 14 days using a starting inoculum of 10 9 CFU/ml. Sixteen DAP-R isolates were recovered from the SEV model: five isolates from 6 mg/kg (D6 isolates from days 2 to 14); five isolates from 8 mg/kg (D8 isolates from days 2 to 8); and six isolates from 10 mg/kg (D10 isolates from days 1 to 14) which were subjected to whole genome sequencing. Reads from each sequenced isolate were mapped against the HOU503 genome for SNP analyses. Variant calling was done with GATK, SamTools, and the low-frequency variant detector from CLC Genomics Workbench 8.5. Variants detected by the three callers were selected and annotated with SnpEff; then compared among the different groups of isolates accordingly to the DAP doses that were exposed.
Results. We detected a total of 16 proteins exhibiting substitutions consistently in all the DAP-R sequenced isolates; including mobile genetic elements (9), hypothetical proteins (2), a bacteriocin, a cysteine desulfurase, a N-acetylglucosamine-specific PTS system, a N-acetylmannosamine-6-phosphate 2-epimerase and a MurR/RpiR, which is a transcriptional regulator that represses the operon MurPQ involved in the uptake and degradation of N-acetylmuramic acid. Notably, mutations in cardiolipin synthase were present only in isolates recovered under D8 dose. The LiaRS substitutions remained in all isolates.
Conclusion. Using a humanized SEV PK/PD model and SNP-based analyses, we were able to uncover possible novel genetic pathways associated with the development DAP-R via the LiaFSR system in enterococci.
Disclosures 
